GammaDelta Therapeutics Appoints Michael Koslowski as CMO

Michael Koslowski, MD

Chief Medical Officer

Michael has over 20 years of experience in immunotherapeutic drug discovery and development from positions in academia, biotech and pharmaceutical industry. 

Michael joined GammaDelta in 2018 from Mission Therapeutics where he was EVP Research & Development and Chief Medical Officer, responsible for developing Mission’s pipeline of deubiquitinating enzyme inhibitors. Prior to joining Mission Therapeutics Michael was VP Clinical Sciences & Early Development at Glenmark Pharmaceuticals where he led all clinical activities to progress Glenmark’s innovative drug portfolio. Before, Michael formed and managed a new group of Translational Medicine Experts at Boehringer Ingelheim to support and drive early drug development activities across all therapeutic areas at BI. Michael was Group Leader New Targets & Antibody Development at Ganymed Pharmaceuticals and a Principal Scientist in Experimental & Translational Oncology at the University of Mainz with focus on cancer drug target identification and development of novel immunotherapeutics.

Michael has a degree in Medicine from the University of Cologne (Germany) and a habilitation degree in Molecular Medicine from the University of Mainz (Germany).